Published in Mech Ageing Dev on September 01, 1978
Metformin for aging and cancer prevention. Aging (Albany NY) (2010) 1.51
The key role of growth hormone-insulin-IGF-1 signaling in aging and cancer. Crit Rev Oncol Hematol (2013) 1.41
Metformin in obesity, cancer and aging: addressing controversies. Aging (Albany NY) (2012) 1.04
Metformin: do we finally have an anti-aging drug? Cell Cycle (2013) 0.98
Metformin for cancer and aging prevention: is it a time to make the long story short? Oncotarget (2015) 0.92
Peculiarities of hyperlipidaemia in tumour patients. Br J Cancer (1981) 0.87
Metformin and the promise of geroprotection. Indian J Endocrinol Metab (2012) 0.82
Hypothalamic mechanisms of ageing and of specific age pathology--II. on the sensitivity threshold of hypothalamo-pituitary complex to homeostatic stimuli in adaptive homestasis. Exp Gerontol (1979) 1.39
Age-associated elevation of hypothalamic, threshold to feedback control, and its role in development, ageine, and disease. Lancet (1971) 1.37
Effect of treatment with phenformin, diphenylhydantoin or L-dopa on life span and tumour incidence in C3H/Sn mice. Gerontology (1980) 1.20
Inhibition of DMBA-induced carcinogenesis by phenformin in the mammary gland of rats. Arch Geschwulstforsch (1978) 1.05
Hypothalmic mechanisms of ageing and of specific age pathology--I. Sensitivity threshold of hypothalamo-pituitary complex to homeostatic stimuli in the reproductive system. Exp Gerontol (1979) 0.91
Potentiation of antitumor effect of cyclophosphamide and hydrazine sulfate by treatment with the antidiabetic agent, 1-phenylethylbiguanide (phenformin). Cancer Lett (1979) 0.88
Peculiarities of hyperlipidaemia in tumour patients. Br J Cancer (1981) 0.87
Neuroendocrine-ontogenetic mechanism of aging: toward an integrated theory of aging. Int Rev Neurobiol (1986) 0.85
Metabolic immunodepression and metabolic immunotherapy: an attempt of improvement in immunologic response in breast cancer patients by correction of metabolic disturbances. Oncology (1982) 0.84
Metabolic immunodepression which increases the risk of cancer. Lancet (1977) 0.83
Hypothalamopituitary hyperactivity and endometrial carcinoma. Qualitative and quantitative disturbances in hormone production. Am J Obstet Gynecol (1968) 0.79
Hypothalamic mechanisms of ageing and of specific age pathology--V. A model for the mechanism of human specific age pathology and natural death. Exp Gerontol (1979) 0.78
Endocrine-metabolic criteria for distinguishing two pathogenetic types of breast cancer. Neoplasma (1977) 0.78
Hyperinsulinemia as a factor modifying sensitivity of endometrial carcinoma to hormonal influences. Eur J Gynaecol Oncol (1993) 0.76
Increase in lifespan of rats following polypeptide pineal extract treatment. Exp Pathol (Jena) (1979) 0.76
Hypothalamic mechanisms of ageing and of specific age pathology--III. Sensitivity threshold of hypothalamo-pituitary complex to homeostatic stimuli in energy systems. Exp Gerontol (1979) 0.76
On the relationship between the activity of acetylation, growth of experimental tumors and efficacy of their suppression by hydrazine sulphate. Oncology (1976) 0.75
Inhibition of lipolytic activity of human growth hormone with sheep prolactin derivative (anaprolactin). Acta Endocrinol (Copenh) (1972) 0.75
Dissociation of hormonal and antigenic activity of luteinizing hormone excreted in endometrial carcinoma patients (endogenous anahormones). Am J Obstet Gynecol (1973) 0.75
New data on three types of anahormones (anahormones of LH, GH, ACTH, lipotropin, calcitonin and parathyroid hormone). Endocrinol Exp (1974) 0.75
Growth hormone, age and the endometrium. N Engl J Med (1970) 0.75
Anahormones of growth hormone, exophthalmic factor, melanophore-stimulating hormone, adrenocorticotropin and gonadotropin in experimental and clinical endocrinology. Int J Cancer (1966) 0.75
[Detection of substances lowering the hypothalamic threshold of homeostatic inhibition. III. Study of Agr 1240]. Agressologie (1977) 0.75
Inhibition of lipolysis and potentiation of the hypoglycaemic effect of insulin by non-hypoglycaemic insulin derivatives. J Endocrinol (1971) 0.75
Effects of misclerone (clofibrate) on dimethylhydrazine-induced intestinal carcinogenesis in rats. Oncology (1982) 0.75
Ageing and cancer in the light of the ontogenetic 'model of medicine'. IARC Sci Publ (1985) 0.75
Age-dependent metabolic immunodepression and cancer. IARC Sci Publ (1985) 0.75
Reversed action of acetylated corticotrophin: inhibition of adreno-cortical secretion. Acta Endocrinol (Copenh) (1969) 0.75
Effect of parathyroid hormone and insulin on extracellular cyclic adenosine-3',5'-monophosphate in patients with benign and malignant breast tumors. Neoplasma (1978) 0.75
Peculiarities of hormonal regulation of adenylate cyclase and lipid composition in colonic and rectal tumors. Neoplasma (1989) 0.75
[Search for drugs reducing the hypothalamic threshold of homeostatic control. 2-Study of Agr-310 and Agr-614 activity and that of a epiphysis extract]. Agressologie (1973) 0.75
Study of the anti-tumor effect of polypeptide pineal extract. Oncology (1979) 0.75
Three models of medicine. (An integrated theory of aging and age-associated diseases). Med Hypotheses (1984) 0.75
[Search for drugs which decrease the hypothalamic threshold of homeostatic inhibition. I. Results of studies of the product Agr-307. (1st conclusions)]. Agressologie (1971) 0.75
Hypothalamic mechanisms of ageing and of specific age pathology--IV. Sensitivity threshold of the hypothalamo-pituitary complex to homeostatic inhibition by thyroid. Exp Gerontol (1979) 0.75
Interrelation between lipidemia and somatomedin activity in cancer and age-associated pathology. Neoplasma (1982) 0.75
Ontogenetic model of ageing and disease formation and mechanisms of natural selection. J Theor Biol (1986) 0.75